The finding could lead to new treatments for this relatively
common disease, in which tissues become overloaded with iron.
About one in every 200 to 300 Americans are affected by hemochromatosis,
which can lead to organ failure if left untreated.
Reporting in the March issue of Cell Metabolism,
researchers at Children's Hospital Boston and Harvard Medical
School study found the protein ferroportin is the major, and
possibly only, iron exporter functioning at key points of
iron absorption and release in the body. This suggests that
iron accumulation in people with hemochromatosis may be the
result of ferroportin-related loss of control over iron export.
"Iron is essential in the body and abundant in the environment,
but it's also very reactive and damaging when in excess. Mammals
have therefore evolved mechanisms to get enough iron from
the diet, but not too much," senior author Nancy Andrews said
in a prepared statement.
She and her colleagues disabled ferroportin in select tissues
and then systemwide in developing mice.
Mice that completely lacked ferroportin died early in development,
due to a failure of iron transfer from mother to embryo. Mice
lacking ferroportin in all tissues except those critical for
nutrient transfer from the mother survived, but quickly become
anemic after birth due to a lack of iron in the blood.
When the researchers examined the intestines, livers and
spleens of these mice, they found an accumulation of iron
within cells. This indicates that the cells aren't able to
release iron once it's absorbed.
Mice that lacked ferroportin in their intestinal cells developed
severe iron deficiency anemia. This further confirmed the
role of ferroportin in iron absorption, the authors said.
More information on Hemochromatosis